Explore the Efficacy and Safety of Once-Daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Non-Valvular Atrial Fibrillation Scheduled for Cardioversion - X-VeRT
Vitamin K antagonists are the standard of care before and after DC cardioversion for atrial fibrillation; however, this poses logistical issues for some patients. The goal of the trial was to evaluate treatment with the novel oral anticoagulant, rivaroxaban, compared with vitamin K antagonists among participants undergoing cardioversion for atrial fibrillation.
Rivaroxaban will allow for safe cardioversion.
- Participants with nonvalvular atrial fibrillation >48 hours (or unknown duration) scheduled for cardioversion
Number of enrollees: 1,504
Mean patient age: 65 years
Percentage female: 27%
- Prior acute thromboembolic event
- MI or stroke ≤14 days (severe disabling stroke ≤3 months)
- TIA ≤3 days
- Cardiac thrombus, myxoma, or valvular heart disease
- Active bleeding or high-risk for bleeding
- Creatinine clearance <30 ml/min
- Long-term aspirin therapy
- Dual antiplatelet therapy
- Efficacy: Composite of cardiovascular death, stroke/TIA, non-CNS systemic embolism, or MI
- Safety: Major bleeding
Participants with nonvalvular atrial fibrillation scheduled for DC cardioversion were randomized to rivaroxaban 20 mg daily (n = 1,002) versus vitamin K antagonist with target international normalized ratio (INR), 2-3 (n = 502).
Participants in whom adequate anticoagulation could be achieved or transesophageal echocardiography performed were administered study medications for 1-5 days (early cardioversion), followed by DC cardioversion, and then resumed on study medication for 42 days.
The remaining participants received study medications for ≥21 days (delayed cardioversion), followed by DC cardioversion, and then resumed on study medication for 42 days.
Overall, 1,504 patients were randomized. The mean age was 65 years, 27% were women, mean CHADS2 score was 1.4, 7.7% had previous stroke/transient ischemic attack (TIA) or systemic embolism, and 20% had diabetes.
In the delayed cardioversion group, the median time to cardioversion was 22 days in the rivaroxaban group vs. 30 days in the vitamin K antagonist group (p < 0.001).
The primary efficacy outcome occurred in 0.51% of the rivaroxaban group vs. 1.02% of the vitamin K antagonist group (95% confidence interval [CI] 0.15-1.73, p = not significant [NS]). In the rivaroxaban group, four events occurred after early cardioversion, while one event occurred after late cardioversion. In the vitamin K antagonist group, three events occurred after early cardioversion, while two events occurred after late cardioversion.
- Hemorrhagic stroke: 2 vs. 0, respectively
- Ischemic stroke: 0 vs. 2, respectively
- Non–central nervous system (CNS) systemic embolism: 0 vs. 1, respectively
- Myocardial infarction (MI): 1 vs. 1, respectively
- Cardiovascular death: 4 vs. 2, respectively
The primary safety outcome occurred in 0.61% of the rivaroxaban group versus 0.80% of the vitamin K antagonist group (95% CI 0.21-2.67, p = NS).
Among patients with nonvalvular atrial fibrillation, the use of rivaroxaban pericardioversion is feasible. This medication was associated with a similar incidence of the primary efficacy outcome and major bleeding compared with a vitamin K antagonist. Rivaroxaban also shortened the time to cardioversion when a delayed strategy was employed.
Cappato R, Ezekowitz MD, Klein AL, et al., on behalf of the X-VeRT Investigators. Rivaroxaban vs. Vitamin K Antagonists for Cardioversion in Atrial Fibrillation. Eur Heart J 2014;Sep 2:[Epub ahead of print].
Presented by Dr. Riccardo Cappato at the European Society of Cardiology Congress, Barcelona, Spain, September 2, 2014.
Keywords: Vitamin K, Myocardial Infarction, Stroke, Ischemic Attack, Transient, Morpholines, Thiophenes, Electric Countershock, Standard of Care, International Normalized Ratio, Embolism, Confidence Intervals, Echocardiography, Transesophageal, Diabetes Mellitus, ESC Congress
< Back to Listings